Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Peñarrubia MJ[au]:

Search results

Items: 40

1.

Polymorphisms in receptors involved in opsonic and non-opsonic phagocytosis and the risk of infection in oncohematological patients.

Herrero-Sánchez MC, Angomás EB, de Ramón C, Tellería JJ, Corchete LA, Alonso S, Ramos MDC, Peñarrubia MJ, Márquez S, Fernández N, García Frade LJ, Sánchez Crespo M.

Infect Immun. 2018 Oct 1. pii: IAI.00709-18. doi: 10.1128/IAI.00709-18. [Epub ahead of print]

PMID:
30275011
2.

A new prognostic model identifies patients aged 80 years and older with diffuse large B-cell lymphoma who may benefit from curative treatment: A multicenter, retrospective analysis by the Spanish GELTAMO group.

Pardal E, Díez Baeza E, Salas Q, García T, Sancho JM, Monzón E, Moraleda JM, Córdoba R, de la Cruz F, Queizán JA, Rodríguez MJ, Navarro B, Hernández JA, Díez R, Vahi M, Viguria MC, Canales M, Peñarrubia MJ, González-López TJ, Montes-Moreno S, González-Barca E, Caballero D, Martín A; GELTAMO Spanish Collaborative Group.

Am J Hematol. 2018 Jul;93(7):867-873. doi: 10.1002/ajh.25107. Epub 2018 May 6.

PMID:
29658143
3.

Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia.

Ribera JM, Morgades M, Montesinos P, Martino R, Barba P, Soria B, Bermúdez A, Moreno MJ, González-Campos J, Vives S, Gil C, Abella E, Guàrdia R, Martínez-Carballeira D, Martínez-Sánchez P, Amigo ML, Mercadal S, Serrano A, López-Martínez A, Vall-Llovera F, Sánchez-Sánchez MJ, Peñarrubia MJ, Calbacho M, Méndez JA, Bergua J, Cladera A, Tormo M, García-Belmonte D, Feliu E, Ciudad J, Orfao A; PETHEMA Group, Spanish Society of Hematology.

Leuk Lymphoma. 2018 Jul;59(7):1634-1643. doi: 10.1080/10428194.2017.1397661. Epub 2017 Nov 22.

PMID:
29165013
4.

Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice.

González-López TJ, Fernández-Fuertes F, Hernández-Rivas JA, Sánchez-González B, Martínez-Robles V, Alvarez-Román MT, Pérez-Rus G, Pascual C, Bernat S, Arrieta-Cerdán E, Aguilar C, Bárez A, Peñarrubia MJ, Olivera P, Fernández-Rodríguez A, de Cabo E, García-Frade LJ, González-Porras JR.

Int J Hematol. 2017 Oct;106(4):508-516. doi: 10.1007/s12185-017-2275-4. Epub 2017 Jun 30.

PMID:
28667351
5.

HLA specificities are associated with prognosis in IGHV-mutated CLL-like high-count monoclonal B cell lymphocytosis.

García-Álvarez M, Alcoceba M, López-Parra M, Puig N, Antón A, Balanzategui A, Prieto-Conde I, Jiménez C, Sarasquete ME, Chillón MC, Gutiérrez ML, Corral R, Alonso JM, Queizán JA, Vidán J, Pardal E, Peñarrubia MJ, Bastida JM, García-Sanz R, Marín L, González M.

PLoS One. 2017 Mar 1;12(3):e0172978. doi: 10.1371/journal.pone.0172978. eCollection 2017.

6.

The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy<sup/>.

Alonso-Álvarez S, Vidriales MB, Caballero MD, Blanco O, Puig N, Martin A, Peñarrubia MJ, Zato E, Galende J, Bárez A, Alcoceba M, Orfão A, González M, García-Sanz R.

Leuk Lymphoma. 2017 May;58(5):1144-1152. doi: 10.1080/10428194.2016.1239263. Epub 2016 Oct 12.

PMID:
27733075
7.

Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice.

González-López TJ, Alvarez-Román MT, Pascual C, Sánchez-González B, Fernández-Fuentes F, Jarque I, Pérez-Rus G, Pérez-Crespo S, Bernat S, Hernández-Rivas JA, Andrade MM, Cortés M, Gómez-Nuñez M, Olivera P, Martínez-Robles V, Fernández-Rodríguez A, Fuertes-Palacio MA, Fernández-Miñano C, de Cabo E, Fisac R, Aguilar C, Bárez A, Peñarrubia MJ, García-Frade LJ, González-Porras JR.

Eur J Haematol. 2016 Sep;97(3):297-302. doi: 10.1111/ejh.12725. Epub 2016 Jan 27.

PMID:
26709028
8.

Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.

Casado LF, García-Gutiérrez JV, Massagué I, Giraldo P, Pérez-Encinas M, de Paz R, Martínez-López J, Bautista G, Osorio S, Requena MJ, Palomera L, Peñarrubia MJ, Calle C, Hernández-Rivas JÁ, Burgaleta C, Maestro B, García-Ormeña N, Steegmann JL.

Cancer Med. 2015 Jul;4(7):995-1002. doi: 10.1002/cam4.440. Epub 2015 Mar 10.

9.

Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia.

González-López TJ, Pascual C, Álvarez-Román MT, Fernández-Fuertes F, Sánchez-González B, Caparrós I, Jarque I, Mingot-Castellano ME, Hernández-Rivas JA, Martín-Salces M, Solán L, Beneit P, Jiménez R, Bernat S, Andrade MM, Cortés M, Cortti MJ, Pérez-Crespo S, Gómez-Núñez M, Olivera PE, Pérez-Rus G, Martínez-Robles V, Alonso R, Fernández-Rodríguez A, Arratibel MC, Perera M, Fernández-Miñano C, Fuertes-Palacio MA, Vázquez-Paganini JA, Gutierrez-Jomarrón I, Valcarce I, de Cabo E, Sainz A, Fisac R, Aguilar C, Paz Martínez-Badas M, Peñarrubia MJ, Calbacho M, de Cos C, González-Silva M, Coria E, Alonso A, Casaus A, Luaña A, Galán P, Fernández-Canal C, Garcia-Frade J, González-Porras JR.

Am J Hematol. 2015 Mar;90(3):E40-3. doi: 10.1002/ajh.23900. Epub 2015 Jan 16.

10.

Do chronic myeloid leukemia patients with late "warning" responses benefit from "watch and wait" or switching therapy to a second generation tyrosine kinase inhibitor?

García-Gutiérrez V, Puerta JM, Maestro B, Casado Montero LF, Muriel A, Molina Hurtado JR, Perez-Encinas M, Moreno Romero MV, Suñol PB, Sola Garcia R, De Paz R, Ramirez Sanchez MJ, Osorio S, Mata Vazquez MI, Martinez López J, Sastre JL, Portero Mde L, Bautista G, Duran Nieto MS, Giraldo P, Jimenez Jambrina M, Burgaleta C, Ruiz Aredondo J, Peñarrubia MJ, Requena MJ, Fernández Valle Mdel C, Calle C, Paz Coll A, Hernández-Rivas JÁ, Franco Osorio R, Cano P, Tallón Pérez D, Fernández de la Mata M, Garrido PL, Steegmann JL.

Am J Hematol. 2014 Nov;89(11):E206-11. doi: 10.1002/ajh.23816. Epub 2014 Aug 27.

11.

Genomic analysis of clonal eosinophils by CGH arrays reveals new genetic regions involved in chronic eosinophilia.

Arefi M, Robledo C, Peñarrubia MJ, García de Coca A, Cordero M, Hernández-Rivas JM, García JL.

Eur J Haematol. 2014 Nov;93(5):422-8. doi: 10.1111/ejh.12379. Epub 2014 Jun 26.

PMID:
24813417
12.

Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement.

Arefi M, García JL, Peñarrubia MJ, Queizán JA, Hermosín L, López-Corral L, Megido M, Giraldo P, de las Heras N, Vanegas RJ, Gutiérrez NC, Hernández-Rivas JM.

Eur J Haematol. 2012 Jul;89(1):37-41. doi: 10.1111/j.1600-0609.2012.01799.x.

PMID:
22587685
13.

Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic Acid and anthracycline-based chemotherapy.

Montesinos P, González JD, González J, Rayón C, de Lisa E, Amigo ML, Ossenkoppele GJ, Peñarrubia MJ, Pérez-Encinas M, Bergua J, Debén G, Sayas MJ, de la Serna J, Ribera JM, Bueno J, Milone G, Rivas C, Brunet S, Löwenberg B, Sanz M.

J Clin Oncol. 2010 Aug 20;28(24):3872-9. doi: 10.1200/JCO.2010.29.2268. Epub 2010 Jul 12.

PMID:
20625122
14.

Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients.

Chillón MC, Santamaría C, García-Sanz R, Balanzategui A, Sarasquete ME, Alcoceba M, Marín L, Caballero MD, Vidriales MB, Ramos F, Bernal T, Díaz-Mediavilla J, García de Coca A, Peñarrubia MJ, Queizán JA, Giraldo P, San Miguel JF, González M.

Haematologica. 2010 May;95(5):745-51. doi: 10.3324/haematol.2009.015073. Epub 2010 Feb 4.

15.

Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide.

Martínez-López J, Rivero A, Rapado I, Montalbán C, Paz-Carreira J, Canales M, Martínez R, Sánchez-Godoy P, Fernández de Sevilla A, Peñalver FJ, Gonzalez M, Prieto E, Salar A, Burgaleta C, Queizán JA, Peñarrubia MJ, Monteagudo MD, Cabrera C, De la Serna J, Tomás JF.

Leuk Lymphoma. 2009 Aug;50(8):1283-9. doi: 10.1080/10428190903040006.

PMID:
19557622
16.

High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics.

Santamaría CM, Chillón MC, García-Sanz R, Pérez C, Caballero MD, Ramos F, de Coca AG, Alonso JM, Giraldo P, Bernal T, Queizán JA, Rodriguez JN, Fernández-Abellán P, Bárez A, Peñarrubia MJ, Vidriales MB, Balanzategui A, Sarasquete ME, Alcoceba M, Díaz-Mediavilla J, San Miguel JF, Gonzalez M.

Leuk Res. 2009 Dec;33(12):1706-9. doi: 10.1016/j.leukres.2009.04.024. Epub 2009 May 19.

PMID:
19457552
17.

Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia.

Santamaría CM, Chillón MC, García-Sanz R, Pérez C, Caballero MD, Ramos F, de Coca AG, Alonso JM, Giraldo P, Bernal T, Queizán JA, Rodriguez JN, Fernández-Abellán P, Bárez A, Peñarrubia MJ, Balanzategui A, Vidriales MB, Sarasquete ME, Alcoceba M, Díaz-Mediavilla J, San Miguel JF, Gonzalez M.

Blood. 2009 Jul 2;114(1):148-52. doi: 10.1182/blood-2008-11-187724. Epub 2009 Apr 27.

18.

Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma.

Garcia-Marco JA, Panizo C, Garcia ES, Deben G, Alvarez-Larran A, Barca EG, Sancho JM, Penarrubia MJ, Garcia-Cerecedo T, Garcia Vela JA.

Cancer. 2009 May 1;115(9):1892-8. doi: 10.1002/cncr.24204.

19.

Hematologic and cytogenetic response to lenalidomide in de novo acute myeloid leukemia with chromosome 5q deletion.

Peñarrubia MJ, Silvestre LA, Conde J, Cantalapiedra A, Garcia Frade LJ.

Leuk Res. 2009 Jun;33(6):e8-9. doi: 10.1016/j.leukres.2008.11.017. Epub 2009 Jan 24. No abstract available.

PMID:
19168219
20.

[Jejunal mucormycosis in a patient with Hodgkin's lymphoma].

Madrigal B, Arenal JJ, Torres A, Peñarrubia MJ, Vara A, Ruiz M, Hernández A, Enríquez P.

Rev Esp Enferm Dig. 2008 Aug;100(8):507-10. Spanish.

21.

The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia.

Santamaría C, Chillón MC, García-Sanz R, Balanzategui A, Sarasquete ME, Alcoceba M, Ramos F, Bernal T, Queizán JA, Peñarrubia MJ, Giraldo P, San Miguel JF, Gonzalez M.

Haematologica. 2008 Dec;93(12):1797-805. doi: 10.3324/haematol.13214. Epub 2008 Sep 24.

22.

Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.

Carreras E, Rosiñol L, Terol MJ, Alegre A, de Arriba F, García-Laraña J, Bello JL, García R, León A, Martínez R, Peñarrubia MJ, Poderós C, Ribas P, Ribera JM, San Miguel J, Bladé J, Lahuerta JJ; Spanish Myeloma Group/PETHEMA.

Biol Blood Marrow Transplant. 2007 Dec;13(12):1448-54.

23.

Is intracranial pressure monitoring in the epidural space reliable? Fact and fiction.

Poca MA, Sahuquillo J, Topczewski T, Peñarrubia MJ, Muns A.

J Neurosurg. 2007 Apr;106(4):548-56.

PMID:
17432703
24.

Oral anticoagulant treatment: risk factors involved in 500 intracranial hemorrhages.

Cantalapiedra A, Gutierrez O, Tortosa JI, Yañez M, Dueñas M, Fernandez Fontecha E, Peñarrubia MJ, García-Frade LJ.

J Thromb Thrombolysis. 2006 Oct;22(2):113-20.

PMID:
17008977
25.

[Primary biliary cirrhosis, "sicca" síndrome and autoimmune hemolytic anemia].

Cantalapiedra A, Peñarrubia MJ, Gutiérrez O, García-Pajares F, Núñez H, García-Frade J, Caro-Patón A.

Rev Esp Enferm Dig. 2005 Sep;97(9):678-9. Spanish. No abstract available.

26.

Experimental and clinical regenerative capability of human bone marrow cells after myocardial infarction.

Fernández-Avilés F, San Román JA, García-Frade J, Fernández ME, Peñarrubia MJ, de la Fuente L, Gómez-Bueno M, Cantalapiedra A, Fernández J, Gutierrez O, Sánchez PL, Hernández C, Sanz R, García-Sancho J, Sánchez A.

Circ Res. 2004 Oct 1;95(7):742-8. Epub 2004 Sep 9.

PMID:
15358665
27.

[Intracoronary stem cell transplantation in acute myocardial infarction].

Avilés FF, San Román JA, García Frade J, Valdés M, Sánchez A, de la Fuente L, Peñarrubia MJ, Fernández ME, Tejedor P, Durán JM, Hernández C, Sanz R, García Sancho J.

Rev Esp Cardiol. 2004 Mar;57(3):201-8. Spanish.

28.

A randomized study of intermediate as compared with high doses of interferon-alpha for chronic myeloid leukemia: no differences in cytogenetic responses.

Peñarrubia MJ, Odriozola J, González C, Massagué I, Miguel A, González San Miguel JD, Pérez Encinas M, Lavilla E, Giraldo MP, Casado LF, Ferrer S, Steegmann JL; Spanish Group on IFN and CML.

Ann Hematol. 2003 Dec;82(12):750-8. Epub 2003 Sep 27.

PMID:
14517691
29.

Emphysematous gastritis and severe aplastic anemia.

Gutierrez O, Cantalapiedra A, Tabuyo MI, Del Villar R, Peñarrubia MJ, Sales R, García-Frade LJ.

Hematol J. 2003;4(1):82-4. Review.

PMID:
12692527
30.

Lack of influence of human immunodeficiency virus infection status in the response to therapy and survival of adult patients with mature B-cell lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study.

Oriol A, Ribera JM, Esteve J, Sanz MA, Brunet S, Garcia-Boyero R, Fernández-Abellán P, Martí JM, Abella E, Sánchez-Delgado M, Peñarrubia MJ, Besalduch J, Moreno MJ, Borrego D, Feliu E, Ortega JJ; PETHEMA Group, Spanish Society of Hematology.

Haematologica. 2003 Apr;88(4):445-53.

31.

Are myeloma patients with renal failure candidates for autologous stem cell transplantation?

San Miguel JF, Lahuerta JJ, García-Sanz R, Alegre A, Bladé J, Martinez R, García-Laraña J, De La Rubia J, Sureda A, Vidal MJ, Escudero A, Pérez-Esquiza E, Conde E, García-Ruiz JC, Cabrera R, Caballero D, Moraleda JM, Leon A, Besalduch J, Hernandez MT, Rifon J, Hernandez F, Solano C, Palomera L, Parody R, Gonzalez JD, Mataix R, Maldonado J, Constela J, Carrera D, Bello JL, De Pablos JM, Pérez-Simón JA, Torres JP, Olanguren J, Prieto E, Acebede G, Peñarrubia MJ, Torres P, Díez-Martín JL, Rivas A, Sánchez JM, Díaz-Mediavilla J.

Hematol J. 2000;1(1):28-36.

PMID:
11920166
32.

[Treatment with lymphoblastoid alpha interferon in patients with chronic myeloid leukemia refractory to recombinant interferon alpha 2].

Steegmann JL, Granados E, Vázquez L, de la Cámara R, Peñarrubia MJ, Fernández-Contreras E, Quiroga JA, Fernández Rañada JM.

Sangre (Barc). 1998 Oct;43(5):443-6. Spanish.

PMID:
9868341
33.

Interferon-alpha lymphoblastoid in chronic myeloid leukemia patients unresponsive to recombinant IFN alpha 2.

Steegmann JL, Granados E, Peñarrubia MJ.

Haematologica. 1997 Nov-Dec;82(6):731-2. No abstract available.

34.

Magnetic resonance imaging features of chloroma of the shoulder.

Gómez N, Ocón E, Friera A, Peñarrubia MJ, Acevedo A.

Skeletal Radiol. 1997 Jan;26(1):70-2.

PMID:
9040149
35.
36.

[Imipenem combined with teicoplanin or vancomycin in the initial empirical treatment of febrile neutropenia. Analysis of the primary response and of a global sequential strategy in 126 episodes].

Figuera A, Tomás JF, Hernández L, Jiménez ML, Peñarrubia MJ, del Rey MC, Arranz R, Cámara R, López-Lorenzo JL, Fernández-Rañada JM.

Rev Clin Esp. 1996 Aug;196(8):515-22. Spanish.

PMID:
8984537
37.

[Allogeneic bone marrow transplantation in chronic myeloid leukemia. The clinical results and risk factors in 70 patients].

Tomás JF, Peñarrubia MJ, García JA, Figuera A, Gómez-García de Soria V, Steegmann JL, Arranz R, Cámara R, Gabriel R, Vázquez L, et al.

Med Clin (Barc). 1995 Nov 11;105(16):605-11. Spanish.

PMID:
8523939
38.

Hypertriglyceridemia may be severe in CML patients treated with interferon-alpha.

Peñarrubia MJ, Steegmann JL, Lavilla E, Casado F, Requena MJ, Picó M, Arranz R, Fernández-Rañada JM.

Am J Hematol. 1995 Jul;49(3):240-1.

PMID:
7604817
39.

Subacute thyroiditis associated with interferon-alpha 2a therapy.

González-Fernández B, Arranz A, Peñarrubia MJ, Marazuela M.

Horm Metab Res. 1995 Jan;27(1):45-6. No abstract available.

PMID:
7729795
40.

[Early bacterial infections in 103 patients treated with bone marrow transplantation].

Tomás JF, Hernández LM, Peñarrubia MJ, Figuera A, Jiménez ML, Cámara R, Arranz R, López JL, Cruz J, Fernández-Rañada JM.

Sangre (Barc). 1994 Jun;39(3):191-6. Review. Spanish.

PMID:
7940049

Supplemental Content

Loading ...
Support Center